Werewolf Therapeutics opened lower at $1.09, compared with its previous close of $1.10. In the last trading session, the stock traded between $1.01 and $1.09. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Werewolf Therapeutics is now worth
$ 6.47
resulting in a loss of
$ 93.53 (93.53%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.09 (-7.82%)
Day High
$1.09
Day Low
$1.01
Day Open
$1.09
Prev Close
$1.10
Volume
1,42,695
1W Return
-0.10%
1M Return
11.92%
3M Return
119.48%
6M Return
49.12%
1Y Return
-35.00%
Fundamentals
Market Cap ($ Mn)
49
PE Ratio
-
PB Ratio
2.81
PEG Ratio
-
ROE
-134.22%
ROCE
-77.18%
EPS (TTM)
$0.08
Investment Returns
1 Week
-0.10%
1 Month
11.92%
3 Months
119.48%
6 Months
49.12%
9 Months
39.94%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
21.0
Jun 26
Updates
21Aug
Werewolf Therapeutics merges with Ambros in $500 million deal
Werewolf Therapeutics merges with Ambros in an all-stock deal valuing Ambros at $500 million. Combined entity secures $150 million private placement to fund Phase 3 trial through 2028. Ambros shareholders retain 71.7% stake; Werewolf shareholders hold 6.8%. Israel Englander reduced Millennium's stake in Werewolf by 53% prior to announcement. Deal follows months of strategic review led by Piper Sandler.
2mo ago
21Aug
Werewolf Therapeutics sells tech platforms to EMD Serono for $33 million
Werewolf Therapeutics shares jumped 89.94% to $0.82 in after-hours trading. Company sold INDUCER and INDUKINE platforms to EMD Serono for $33 million total. $28 million paid upfront with $5 million due upon asset transfer finalization. Werewolf retains full rights to clinical programs WTX-124 and WTX-330. Stock remains down 66.31% over the past 12 months despite the deal.
2mo ago
31Jul
Werewolf Therapeutics Q2 EPS of $0.08 beats $(0.29) estimate
Werewolf Therapeutics turned profitable in Q2 with EPS of $0.08, beating estimates by 127.59%. Driven by $21.0 million in sales from a Jazz Pharmaceuticals deal, the company repaid all debt and holds $22.0 million in cash, providing runway into Q2 2027.
